TABLE 2.

Evaluation of the combinatorial effect of ExtTa with DOX and 5-FU in Saos-2 osteosarcoma and HCT116 colorectal cancer cells, respectively.

	ExtTa (μg/mL)	DOX (μg/mL)	Fa	CI	Effect
Saos-2	0.781	0.006	0.61	0.20203	Synergism
	1.563	0.112	0.45	1.06995	Antagonism
	3.125	0.224	0.41	2.75892	Antagonism
	6.250	0.450	0.50	3.14533	Antagonism
	12.500	0.900	0.62	3.04077	Antagonism
	25.000	0.180	0.84	1.31011	Antagonism
	50.000	0.360	0.96	0.59225	Synergism
	100.000	0.720	0.99	0.41492	Synergism

	ExtTa (μg/mL)	5-FU (μg/mL)	Fa	CI	Effect
HCT116	0.32	0.49	0.29	1.49333	Antagonism
	0.63	0.98	0.47	0.77004	Synergism
	1.25	1.95	0.54	0.66478	Synergism
	2.50	3.90	0.61	1.22185	Antagonism
	5.00	7.81	0.67	1.64750	Antagonism
	10.00	15.63	0.70	2.68580	Antagonism
	20.00	31.25	0.85	1.55373	Antagonism
	40.00	62.50	0.97	0.32131	Synergism

ExtTa, T. asperelloides ethanolic extract; DOX, doxorubicin; 5-FU, 5-Fluorouracil; Fa, fraction inhibition; CI, combination index.